Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vimta Labs's Days Sales Outstanding for the
three
months ended in Jun. 2026 was 88.43.
Vimta Labs's Days Inventory for the
three
months ended in Jun. 2026 was 120.53.
Vimta Labs's Days Payable for the
three
months ended in Jun. 2026 was 46.92.
Therefore, Vimta Labs's Cash Conversion Cycle (CCC) for the
three
months ended in Jun. 2026 was 162.04.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Vimta Labs Cash Conversion Cycle Related Terms
Vimta Labs Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Vimta Labs's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:524394 vs TMO, DHR, IDXX: Cash Conversion Cycle Comparison
For the Diagnostics & Research subindustry, Vimta Labs's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vimta Labs Cash Conversion Cycle vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Vimta Labs's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Vimta Labs's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Vimta Labs's Cash Conversion Cycle for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vimta Labs (BOM:524394) has a Cash Conversion Cycle of 162.04 as of Jun. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Vimta Labs and its competitors.
Is Vimta Labs' Cash Conversion Cycle too high?
Vimta Labs' current Cash Conversion Cycle is 162.04. The Medical Diagnostics & Research industry median Cash Conversion Cycle is 69.76. Vimta Labs' value of 162.04 is 132.3% above this industry median. Overall, Vimta Labs has a GF Score™ of 84/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vimta Labs' Cash Conversion Cycle compare to TMO and DHR?
Vimta Labs' Cash Conversion Cycle of 162.04 can be compared against companies in the Medical Diagnostics & Research industry. The industry median Cash Conversion Cycle is 69.76. Vimta Labs' value of 162.04 is 132.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Medical Diagnostics & Research company?
The median Cash Conversion Cycle among Medical Diagnostics & Research companies is 69.76, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vimta Labs's current Cash Conversion Cycle of 162.04 is 132.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Vimta Labs and its competitors. For the Medical Diagnostics & Research industry, the median Cash Conversion Cycle is 69.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vimta Labs's current Cash Conversion Cycle is 162.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vimta Labs stock overvalued right now?
Based on GuruFocus' analysis, Vimta Labs (BOM:524394) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹495.16, compared to a current price of ₹641.20 — trading 29.5% above its estimated fair value. The current Cash Conversion Cycle is 162.04 and 132.3% above the Medical Diagnostics & Research industry median of 69.76. Vimta Labs' overall GF Score™ is 84/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Vimta Labs (BOM:524394), the current Cash Conversion Cycle is 162.04 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vimta Labs (BOM:524394) Overvalued in 2026?
Based on GuruFocus' analysis, Vimta Labs stock appears to be overvalued.
The current stock price of ₹641.20 is trading 29.5% above its estimated GF Value™ of ₹495.16.
GuruFocus considers Vimta Labs to be Modestly Overvalued.
Key valuation signals for BOM:524394:
Cash Conversion Cycle: 162.04
GF Value™: ₹495.16 vs. price of ₹641.20 (29.5% above fair value)
Industry Position: 132.3% above the Medical Diagnostics & Research median
No single metric tells the full story. See the BOM:524394 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vimta Labs Ltd is a comprehensive contract research and testing organization, providing a wide range of services to pharmaceutical, biopharmaceutical, food, consumer goods, electronic, electrical, agrochemical, healthcare, medical device, and many other industries. Its services portfolio includes testing and contract research services in the fields of clinical research, pre-clinical research, clinical diagnostics, biopharma services, analytical testing, research and environmental studies, and Others. It has only one reportable segment namely Contract Research and Testing Services which generates the revenue.
84GF Score
Get the complete analysis for BOM:524394
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524394 has been successfully added to your 
